QuattroTi DenTech has been working in the dental field for 35 years and is proud of having created unique, exclusive intra-oral devices, made from a special thermoplastic material, used by specialists to prevent, protect and cure

SIFI was established in Catania in 1935. Retaining its exclusive focus on Eye Care, the company has grown over time, extending its business activities beyond pharmaceuticals, to also embrace surgery and diagnostics.

Montefarmaco OTC ranks among the Italian leading over-the-counter (OTC) manufacturers. It provides a wide range of pharmaceutical products that enhance your well-being: self-medication drugs, dietary products, para pharmaceuticals, medical devices and cosmetics.

ZambonCelebrating one hundred years of timeless values ( 1906 - 2006 ), Zambon is a leading pharmaceutical and chemical multinational with a reputation for inventive and innovative thinking, flexibility and customer focus. The technologies of interest are those showing the potential to generate innovative products bringing real benefits to patients in the therapeutic areas relevant for the parent company

Founded by Swiss researchers in 1945, IBSA (Institute Biochimique SA) has gained unique experience in pharmaceutical research, development and technology. IBSA began to develop more and more innovative pharmaceutical forms from the 1980s onwards, optimising the efficacy and tolerability of the active ingredients, increasing patient compliance and improving the therapeutic outcome as a result. In Italy IBSA is represented by two trading companies, IBSA Farmaceutici Italia srl and Amsa srl, owners of proprietary medicines, and by Gelfipharma International srl, a production plant which boasts high quality standards in the pharmaceutical and nutritional (softpearls) fields and in the production of medical devices. Every year, Gelfipharma International produces over 500,000 syringe vials pre-filled with hyaluronic acid for the international market, in compliance with GMP standards.

Lisoma International Ltd has the international rights to Herstat (3% propolis ACF ointment) for the treatment of the symptoms of herpes simplex lesions, or cold sores. The company was established in the UK in 1999(originally as Hela International Ltd), to deal with regulatory, licensing and marketing issues and to appoint distributors for Herstat products, worldwide.

The Nasaleze story all began one day in 1990... Mike James was working in a factory making cosmetic facemasks using a number of ingredients. Mike noticed that despite there usually being clouds of white powder in the air nobody ever sneezed. At the same time his teenage son was suffering terribly from allergies, sneezing almost constantly. Mike’s mind was cast back to the clouds of white powder in the factory. The following day he brought home some of this (cellulose) powder and suggested his sneezing son should ‘sniff’ some of the powder off the back of his hand. The sneezing stopped in a matter of seconds and all the other symptoms subsided over the next few minutes. Mike immediately set about researching and developing his idea, including creating the unique and patented special delivery system. After the initial research proved encouraging Mike was ready to bring his invention to market. The Medicines Control Agency looked into the issue in greater detail and came to the conclusion that Nasaleze was in fact a low risk product, not a drug and that it should be registered as a Class 1 Medical Device under EU Directive 93/42/EEC. Nasaleze is now distributed in over 30 countries worldwide and is gaining respect from the Medical Community after successive and successful clinical studies.

One of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas. The group owns modern, sophisticated industrial plants at which it manufactures its proprietary drugs to the highest quality standards. The first plant, at which injectables and solid oral drugs are manufactured, is situated in Milan, and a second manufacturing unit, for the production of liquid oral drugs, is located in Madrid. In addition to its pharmaceutical activities in the field of ethical drugs, Italfarmaco also markets generic drugs through the company Lifepharma.